PanGen Biotech Shares Owned By Insiders vs. Current Valuation

222110 Stock  KRW 5,720  260.00  4.76%   
Considering the key profitability indicators obtained from PanGen Biotech's historical financial statements, PanGen Biotech may not be well positioned to generate adequate gross income at the moment. It has a very high risk of underperforming in January. Profitability indicators assess PanGen Biotech's ability to earn profits and add value for shareholders.
For PanGen Biotech profitability analysis, we use financial ratios and fundamental drivers that measure the ability of PanGen Biotech to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well PanGen Biotech utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between PanGen Biotech's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of PanGen Biotech over time as well as its relative position and ranking within its peers.
  
Check out Trending Equities.
Please note, there is a significant difference between PanGen Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if PanGen Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, PanGen Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

PanGen Biotech Current Valuation vs. Shares Owned By Insiders Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining PanGen Biotech's current stock value. Our valuation model uses many indicators to compare PanGen Biotech value to that of its competitors to determine the firm's financial worth.
PanGen Biotech is rated third in shares owned by insiders category among its peers. It is rated fourth in current valuation category among its peers reporting about  2,727,353,403  of Current Valuation per Shares Owned By Insiders. Comparative valuation analysis is a catch-all model that can be used if you cannot value PanGen Biotech by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for PanGen Biotech's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.

PanGen Current Valuation vs. Shares Owned By Insiders

Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.

PanGen Biotech

Insiders Shares

 = 

Executives Shares

+

Employees

 = 
33.33 %
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.

PanGen Biotech

Enterprise Value

 = 

Market Cap + Debt

-

Cash

 = 
90.89 B
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.

PanGen Current Valuation vs Competition

PanGen Biotech is rated fourth in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Biotechnology industry is presently estimated at about 7.34 Trillion. PanGen Biotech claims roughly 90.89 Billion in current valuation contributing just under 2% to stocks in Biotechnology industry.

PanGen Biotech Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in PanGen Biotech, profitability is also one of the essential criteria for including it into their portfolios because, without profit, PanGen Biotech will eventually generate negative long term returns. The profitability progress is the general direction of PanGen Biotech's change in net profit over the period of time. It can combine multiple indicators of PanGen Biotech, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
PanGen Biotech Inc. operates as a specialized biologics company in South Korea. The company was founded in 1999 and is based in Suwon, South Korea. PanGen is traded on Korean Securities Dealers Automated Quotations in South Korea.

PanGen Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on PanGen Biotech. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of PanGen Biotech position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the PanGen Biotech's important profitability drivers and their relationship over time.

Use PanGen Biotech in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if PanGen Biotech position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in PanGen Biotech will appreciate offsetting losses from the drop in the long position's value.

PanGen Biotech Pair Trading

PanGen Biotech Pair Trading Analysis

The ability to find closely correlated positions to PanGen Biotech could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace PanGen Biotech when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back PanGen Biotech - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling PanGen Biotech to buy it.
The correlation of PanGen Biotech is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as PanGen Biotech moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if PanGen Biotech moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for PanGen Biotech can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your PanGen Biotech position

In addition to having PanGen Biotech in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Theme ETFs Thematic Idea Now

Theme ETFs
Theme ETFs Theme
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Theme ETFs theme has 483 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Theme ETFs Theme or any other thematic opportunities.
View All  Next Launch

Other Information on Investing in PanGen Stock

To fully project PanGen Biotech's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of PanGen Biotech at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include PanGen Biotech's income statement, its balance sheet, and the statement of cash flows.
Potential PanGen Biotech investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although PanGen Biotech investors may work on each financial statement separately, they are all related. The changes in PanGen Biotech's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on PanGen Biotech's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.